In the clinical trial for hemophilia B, hepatic gene delivery with AAV2 vectors achieved transient (~6 weeks) yet therapeutic expression of coagulation factor IX (FIX) but subsequent CD8+ T cell response destroyed AAV infected hepatocytes (Manno et al., 2006; Mingozzi et al., 2007). Here, F9 is linked to hemophilia B.